Israel’s Silexion Therapeutics reported that its SIL-204 pancreatic cancer treatment effectively reduces primary tumor growth and secondary cancer spread. Silexion ‘s first generation LODER treatment already had good results in Phase 2 trials on “simple” cancers.
https://silexion.com/wp-content/uploads/2025/02/silexion-therapeutics-announces-completion-of1.pdf